Structural Characterization of Inhibitor Complexes with Checkpoint Kinase 2 (Chk2), a Drug Target for Cancer Therapy.Lountos, G.T., Jobson, A.G., Tropea, J.E., Self, C.R., Zhang, G., Pommier, Y., Shoemaker, R.H., Waugh, D.S.
(2011) J.Struct.Biol. 176: 292
- PubMed: 21963792
- DOI: 10.1016/j.jsb.2011.09.008
- Primary Citation of Related Structures:
- PubMed Abstract:
- Crystal Structure of Checkpoint Kinase 2 in Complex with Nsc 109555, a Potent and Selective Inhibitor.
Lountos, G.T.,Tropea, J.E.,Zhang, D.,Jobson, A.G.,Pommier, Y.,Shoemaker, R.H.,Waugh, D.S.
(2009) Protein Sci. 18: 92
Chk2 (checkpoint kinase 2) is a serine/threonine kinase that participates in a series of signaling networks responsible for maintaining genomic integrity and responding to DNA damage. The development of selective Chk2 inhibitors has recently attracte ...
Chk2 (checkpoint kinase 2) is a serine/threonine kinase that participates in a series of signaling networks responsible for maintaining genomic integrity and responding to DNA damage. The development of selective Chk2 inhibitors has recently attracted much interest as a means of sensitizing cancer cells to current DNA-damaging agents used in the treatment of cancer. Additionally, selective Chk2 inhibitors may reduce p53-mediated apoptosis in normal tissues, thereby helping to mitigate adverse side effects from chemotherapy and radiation. Thus far, relatively few selective inhibitors of Chk2 have been described and none have yet progressed into clinical trials. Here, we report crystal structures of the catalytic domain of Chk2 in complex with a novel series of potent and selective small molecule inhibitors. These compounds exhibit nanomolar potencies and are selective for Chk2 over Chk1. The structures reported here elucidate the binding modes of these inhibitors to Chk2 and provide information that can be exploited for the structure-assisted design of novel chemotherapeutics.
Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702-1201, USA.